Methylene Blue Does Not Improve Vasoplegia After Left Ventricular Assist Device Implantation
- 1 March 2021
- journal article
- research article
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 111 (3) , 800-808
Abstract
No abstract availableKeywords
Funding Information
- Abbott Laboratories
This publication has 21 references indexed in Scilit:
- Vasoactive-Inotropic Score Is Associated With Outcome After Infant Cardiac SurgeryPediatric Critical Care Medicine, 2014
- Methylene Blue is Associated With Poor Outcomes in Vasoplegic ShockJournal of Cardiothoracic and Vascular Anesthesia, 2013
- Con: Methylene Blue Should Not Be Used Routinely for Vasoplegia PerioperativelyJournal of Cardiothoracic and Vascular Anesthesia, 2011
- Vasoplegia During Cardiac Surgery: Current Concepts and ManagementSeminars in Thoracic and Cardiovascular Surgery, 2010
- Early On–Cardiopulmonary Bypass Hypotension and Other Factors Associated With Vasoplegic SyndromeCirculation, 2009
- Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgeryThe Annals of Thoracic Surgery, 2004
- Methylene blue: the drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypassThe Journal of Thoracic and Cardiovascular Surgery, 2003
- Management of vasodilatory shock after cardiac surgery: Identification of predisposing factors and use of a novel pressor agentThe Journal of Thoracic and Cardiovascular Surgery, 1998
- Cytokine Responses to Cardiopulmonary Bypass: Lessons Learned From Cardiac TransplantationThe Annals of Thoracic Surgery, 1997
- Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation.Journal of Clinical Investigation, 1995